

FAX



GlaxoSmithKline

NOV. 16 2005

To Attn: Art Unit 2613

Company USPTO

Fax 703-746-9195

From Valerie L. Phillips

Tel 919-483-8223 **Fax** 919-483-5730

E-mail Vlp47157@gsk.com

Date November 16, 2005 **Pages including cover** 1

Subject Request for Corrected Filing Receipt

Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

Serial No.: 10/533,325
Filing Date: 6/2/2005
Applicant: Goodson et al.
Title: Pharmaceutical Antiviral Compositions

Attached:
Certificate of transmission via facsimile
Request for Corrected Filing Receipt
Copy of Official Filing Receipt

Thank you,
Valerie Phillips

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this Request for Corrected Filing Receipt is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-746-9195) on November 16, 2005.

Valerie L. Phillips
Valerie L. Phillips

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

PU5025USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

NOV. 16 2005

In re Application of: Goodson et al.
 Serial No.: 10/533,325
 Filed: May 2, 2005
 For: Pharmaceutical Antiviral Compositions

Art Unit: 2613
 Examiner:

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450


REQUEST FOR CORRECTED FILING RECEIPT

- Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.
- There is an error with respect to the following data, which is:

3. incorrectly entered and/or omitted.

Error in	Correct data
1. <input type="checkbox"/> Appln't's name:	1.
2. <input type="checkbox"/> Applicant's address:	2.
3. <input type="checkbox"/> Title	3.
4. <input type="checkbox"/> Filing date	4.
5. <input type="checkbox"/> Serial Number	5.
6. <input type="checkbox"/> Foreign Applications	6.
7. <input checked="" type="checkbox"/> Other -- Assignment for Published Patent Application: Glaxo Group Unlimited and SmithKline Beecham Corp., Research Triangle Park, NC	7. Assignment for Published Patent Application: Glaxo Group Limited and SmithKline Beecham Corp., Philadelphia, PA

4. Charge Account 07-1392 for any fees which may be due.


 Karen L. Prus
 Registration No.: 39,337

Date: November 15, 2005
 GlaxoSmithKline
 Five Moore Drive, P.O. Box 13398
 Research Triangle Park, NC 27709
 Phone: 919-483-2192
 Fax: 919-483-7988

CERTIFICATE OF MAILING/TRANSMISSION (37 CFR 1.8)

I hereby certify that this correspondence is, on the date shown below, being:

MAILING

deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

Date: 11/16/05

FACSIMILE

Transmited by facsimile to the Patent and Trademark Office.


 Signature
 Valerie L. Phillips



UNITED STATES PATENT AND TRADEMARK OFFICE

HPM/KEP/Val
 UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/533,325	05/02/2005	2613	900	PU5025USW		17	3

23347
 GLAXOSMITHKLINE
 CORPORATE INTELLECTUAL PROPERTY, MAI B475
 FIVE MOORE DR., PO BOX 13398
 RESEARCH TRIANGLE PARK, NC 27709-3398

CONFIRMATION NO. 5293

FILING RECEIPT

"OC000000016972685"

Date Mailed: 09/14/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Gary Wayne Goodson, Durham, NC;
 Alison Green Floyd, Durham, NC;
 Cecilia Carpenter Navy, Durham, NC;

Assignment For Published Patent Application

Glaxo Group ~~Unlimited~~ and Smithkline Beecham Corp., Research Triangle Park, NC

Power of Attorney: The patent practitioners associated with Customer Number 23347.

Domestic Priority data as claimed by applicant


This application is a 371 of PCT/US03/35830 11/07/2003
 which claims benefit of 60/425,182 11/08/2002

Foreign Applications

Projected Publication Date: 12/15/2005

Non-Publication Request: No

Early Publication Request: No



Title

Pharmaceutical compositions

Preliminary Class

348

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An International (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4168).

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184. If the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof

unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/533,325	Gary Wayne Goodson	PU5025USW
		INTERNATIONAL APPLICATION NO.
		PCT/US03/35830
23347 GLAXOSMITHKLINE CORPORATE INTELLECTUAL PROPERTY, MAI B475 FIVE MOORE DR., PO BOX 13398 RESEARCH TRIANGLE PARK, NC 27709-3398	I.A. FILING DATE	PRIORITY DATE
	11/07/2003	11/08/2002
CONFIRMATION NO. 5293 371 ACCEPTANCE LETTER		
 OC000000016972666		

Date Mailed: 09/14/2005

NOTICE OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C 371 AND 37 CFR 1.495

The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495), has determined that the above identified international application has met the requirements of 35 U.S.C. 371, and is ACCEPTED for national patentability examination in the United States Patent and Trademark Office.


The United States Application Number assigned to the application is shown above and the relevant dates are:

<u>05/02/2005</u>	<u>05/02/2005</u>
DATE OF RECEIPT OF 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) REQUIREMENTS	DATE OF COMPLETION OF ALL 35 U.S.C. 371 REQUIREMENTS

A Filing Receipt (PTO-103X) will be issued for the present application in due course. **THE DATE APPEARING ON THE FILING RECEIPT AS THE "FILING DATE" IS THE DATE ON WHICH THE LAST OF THE 35 U.S.C. 371 (c)(1), (c)(2) and (c)(4) REQUIREMENTS HAS BEEN RECEIVED IN THE OFFICE. THIS DATE IS SHOWN ABOVE.** The filing date of the above identified application is the international filing date of the International application (Article 11(3) and 35 U.S.C. 363). Once the Filing Receipt has been received, send all correspondence to the Group Art Unit designated thereon.

The following items have been received:

- Copy of the International Application filed on 05/02/2005
- Copy of the International Search Report filed on 05/02/2005
- Copy of IPE Report filed on 05/02/2005
- Preliminary Amendments filed on 05/02/2005
- Information Disclosure Statements filed on 05/02/2005
- Oath or Declaration filed on 05/02/2005
- Request for Immediate Examination filed on 05/02/2005
- U.S. Basic National Fees filed on 05/02/2005
- Priority Documents filed on 05/02/2005
- Power of Attorney filed on 05/02/2005
- Specification filed on 05/02/2005



NOV. 16, 2005 10:25AM

GW GLOBAL R&D IS

NO. 0074 P₅ 7 of 2

- Claims filed on 05/02/2005

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

KAYA L LEWIS BALTIMORE
Telephone: (703) 308-9140 EXT 202

PART 1 - ATTORNEY/APPLICANT COPY

FORM PCT/DO/EO/903 (371 Acceptance Notice)